Source comparison
BPC-157 Skin Health Protocol Dosage Timing: Research vs Clinical Application Comparison
Total Daily Dose 10–20mcg/kg body weight (rodent models scaled to human equivalent: ~200–400mcg for 70kg adult) 250–500mcg/day standard; up to 1,000mcg/day for severe damage Start at 250mcg twice daily; increase only if response plateaus after 14 days Injectio
This comparison does not assign a generated winner or score.
- Total Daily Dose
- 10–20mcg/kg body weight (rodent models scaled to human equivalent: ~200–400mcg for 70kg adult)
- 250–500mcg/day standard; up to 1,000mcg/day for severe damage
- Start at 250mcg twice daily; increase only if response plateaus after 14 days
- Injection Frequency
- Once or twice daily in controlled studies
- Twice daily (12-hour intervals) for sustained coverage
- Single daily dosing wastes half the therapeutic window
- Administration Route
- Subcutaneous or intraperitoneal in animal models
- Subcutaneous only for human application; inject within 2–4 inches of target tissue when possible
- Local injection provides 2× higher tissue concentrations vs distant sites
- Treatment Duration
- 14–28 days in acute wound studies; up to 8 weeks for chronic conditions
- Minimum 21 days for visible dermal improvement; 6–8 weeks for scar remodeling
- Collagen remodeling requires sustained signaling. Short courses underperform
- Expected Timeline
- VEGF upregulation detectable at 48–72 hours; angiogenesis visible by day 5–7
- Subjective improvement (reduced inflammation, faster epithelialization) within 7–10 days
- Cosmetic improvement lags biological markers by 2–3 weeks
- Storage Requirements
- −20°C for lyophilized powder; 2–8°C post-reconstitution
- Refrigerate at 2–8°C after mixing; discard after 30 days
- Temperature excursions above 8°C denature peptide irreversibly